Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1992 May;118(5):371–376. doi: 10.1007/BF01294442

Radioiodinated anti-hepatocellular carcinoma (HCC) ferritin Targeting therapy, tumor imaging and anti-antibody response in HCC patients with hepatic arterial infusion

Zhen Fan 1, Zhaoyou Tang 1,✉, Kangda Liu 1, Dong Zhou 1, Jizhen Lu 1, Aina Yuan 2, Huiyang Zhao 2
PMCID: PMC12201709  PMID: 1316355

Abstract

Radioimmunoimaging and radioimmunotherapy with radioiodinated anti-(hepatocellular carcinoma ferritin) antibody (131I-or125I-FtAb) have been applied in patients with primary liver cancer. A total of 41 patients with surgically unresectable hepatocellular carcinoma (HCC) and receiving hepatic artery ligation and cannulation during exploratory laparotomy were treated with this regimen by intrahepatic arterial infusion. Compared with the control group, a decline of serum α-fetoprotein (65.7% versus 42.9%) and shrinkage of tumor (68.3% versus 33.9%) were observed in the treated group, and a higher second-look resection rate (31.7% versus 5.1%) and longer survival (1-year: 61.0% versus 37.3%, 3-year: 25.0% versus 6.9%) resulted. The administration of antibody through a hepatic arterial catheter (n=16) was compared with intravenous injection (n-17) in terms of the tumor-imaging sensitivity in 33 patients with liver cancer. The results indicated that hepatic arterial infusion was superior to intravenous injection. The sensitivity 7 days after the administration was 100% in the i.a. group and 76.5% in the i.v. group, the uptake ratio of tumor to liver being 1.74±0.57 in the former and 1.34±0.29 in the latter. Furthermore, intrahepatic arterial infusion revealed a lower anti-antibody detection rate than intravenous injection (0/14 versus 4/11).

Key words: Hepatocellular carcinoma, Radioimmunoimaging, Radioimmunotherapy, anti-ferritin, Hepatic arterial infusion

Abbreviations

AFP

α-tetoprotein

FtAb

ferritin antibody

References

  1. Beatty BG, O'Connor-Tressel M, Do T, Paxton RJ, Beatty JD (1990) Mechanism of decreasing liver uptake of111In-labeled anti-carcinoembryonic antigen monoclonal antibody by specific antibody pretreatment in tumor bearing mice. Cancer Res 50:846–851 [PubMed] [Google Scholar]
  2. Carrasquillo JA, Sugarbaker P, Colcher D, Reynolds JC, Esteban J, Bryant G, Keenan AM, Perentesis P, Yokoyama K, Simpson DE, Ferroui P, Farkas R, Schlom J, and Larson SM (1988) Radioimmunoscintigraphy of colon cancer with iodine-131-labeled B72.3 monoclonal antibody. J Nucl Med 29:1022–1033 [PubMed] [Google Scholar]
  3. Cobb LM, Humm JL (1986) Radioimmunotherapy of malignancy using antibody targeted radionuclides. Br J Cancer 54:863–870 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Courtenay-Luck N, Epenetos AA, Moore R, Larche M, Pectaside D, Dhokia B, Ritter MA (1986) Development of primary and secondary immune response to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neaplasms. Cancer Res 46:6489–6493 [PubMed] [Google Scholar]
  5. Dykes PW, Bradwell AR, Chapman CE, Vaughan ATM (1987) Radioimmunotherapy of cancer: clinical studies and limiting factors. Cancer Treat Rev 14:87–106 [DOI] [PubMed] [Google Scholar]
  6. Epenetos AA, Kosmas C (1989) Monoclonal antibodies for imaging and therapy. Br J Cancer 59:152–155 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fu KK, Rayner PA, Lam KN (1984) Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion. Int J Radiat Oncol Biol Phys 10:1473–1478 [DOI] [PubMed] [Google Scholar]
  8. Fu KK, Lam KN, Rayner PA (1985) The influence of cis-platinum administration and low dose irradiation (CLDRI) on their combined effects on a murine squamous cell carcinoma. Int J Radiat Oncol Biol Phys 11:2119–2124 [DOI] [PubMed] [Google Scholar]
  9. Goldenberg DM, Deland F, Kim E, Bennet S, Primus FJ, Nagell JR van Jr, Estes N, DeSimone P, Rayburn P (1978) Use of radiolabeled antibodies to carconoembryonic antigen for the detection and localization of diverse cancers by photoscanning. N Engl J Med 298:1384–1388 [DOI] [PubMed] [Google Scholar]
  10. Halpern SE, Dillman RO (1987) Problems associated with radioimmunodetection and possibilities for future solutions. J Biol Response Mod 6:235–262 [PubMed] [Google Scholar]
  11. Jain RK (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res [Suppl] 50:814–819 [PubMed] [Google Scholar]
  12. Liu AY, Robinson RR, Hellström KE, Murray ED Jr, Chang CP, Hellström I (1987a) Chimetric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA 84:3439–3443 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Liu AY, Robinson RR, Murray ED Jr, Ledbetter JA, Hellström I, Hellström KE (1987b) Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol 139:3521–3526 [PubMed] [Google Scholar]
  14. Liu KD, Tang ZY, Bao YM, Lu JZ, Qian F, Yuan AN, Zhao HY (1989) Radioimmunotherapy for hepatocellular carcinoma (HCC) using131I anti-HCC isoferritin IgG: preliminary results of experimental and clinical studies. Int J Radiat Oncol Biol Phys 16:319–323 [PubMed] [Google Scholar]
  15. Matzku S, Tilgen W, Kalthoff H, Schmiegel WH, Brocker E-B (1988) Dynamics of antibody transport and internalization. Int J Cancer [Suppl] 2:11–14 [DOI] [PubMed] [Google Scholar]
  16. Moroz C, Lantsberg Z, Sela O, Cohen Y, Khodadadi J, Goldstein J, Quastel MR, Shoenfeld Y (1989) Radioimmunodetection of tumors with monoclonal antiplacental ferritin antibody: preliminary results. Oncology 46:35–39 [DOI] [PubMed] [Google Scholar]
  17. Order SE, Stillwagon GB, Klein JL, Leichner PK, Siegelman SS, Fishman EK, Ettinger DS, Haulk T, Kopher KA, Finney K, Surdyke M, Selt S, Leibel S (1985)131I antiferritin, a new treatment modality in hepatoma: an RTOG study. J Clin Oncol 3:1573–1582 [DOI] [PubMed] [Google Scholar]
  18. Order SE, Klein JL, Leichner PK (1987) Hepatoma: model for radiolabeled antibody in cancer treatment. NCI Monogr 3:37–41 [PubMed] [Google Scholar]
  19. Parker BA, Vasso AB, Halpern SE, Miller RA, Hupf H, Amox DG, Simoni JL, Starr RJ, Green MK, Royston I (1990) Radioimmunotherapy of human B-cell lymphoma with90Y conjugated antiidiotype monoclonal antibody. Cancer Res [Suppl] 50:1022–1028 [PubMed] [Google Scholar]
  20. Pressman D (1957) Radiolabeled antibodies. Proc Natl Acad Sci USA 69:644–650 [DOI] [PubMed] [Google Scholar]
  21. Pressman D, Korngold L (1953) The in vivo localization of anti-Wagner osteogenic sarcoma antibodies. Cancer 6:619–623 [DOI] [PubMed] [Google Scholar]
  22. Schlom J, Hand PH, Greiner JW, Colcher D, Shrivastav S, Carrasquillo JA, Reynolds JC, Larson SM, Raubitschek A (1990) Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. Cancer Res [Suppl] 50:820–827 [PubMed] [Google Scholar]
  23. Stickney DR, Slater JB, Kirk GA, Ahlem C, Chang C-H, Frincke JM (1989) Bifunctional antibody: ZCE/CHA111indium BLEDTA-IV clinical imaging in colorectal carcinoma. Antibody Immunoconj Radiopharmacol 2:1–13 [Google Scholar]
  24. Stewart JSW, Hird V, Snook D, Sullivan M, Hooker G, Courtenay-Luck N, Sivolapenko G, Griffiths M, Myers MJ, Lambert HE, Munro AJ, Eppentos AA (1989) Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity and efficacy of I-131 labeled monoclonal antibodies. Int J Radiat Oncol Biol Phys 16:405–413 [DOI] [PubMed] [Google Scholar]
  25. Tang ZY (1989) Effects in the past decades to improve the ultimate outcome of primary liver cancer. In: Tang ZY, Wu MC, Xia SS (eds) Primary liver cancer. Springer, Berlin Heidelberg New York pp 469–481 [Google Scholar]
  26. Tang ZY, Liu KD, Guo YD, Ma ZC, Yu D, Yu ZY, Bao YM, Lu JZ, Lin ZY, Yu YQ, Zhao HY, Chen KJ, Qian F, Yuan AN, Wu ZM (1986) Tumor imaging and target therapy for hepatocellular carcinoma — preliminary results of experimental and clinical studies. Chin Med J 99:855–860 [PubMed] [Google Scholar]
  27. Tang ZY, Liu KD, Bao YM, Lu JZ, Yu YQ, Ma ZC, Zhou XD, Yang R, Gan YH, Lin ZY, Fan Z, Hou Z (1990) Radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma with reference to second look resection. Cancer 65:211–215 [DOI] [PubMed] [Google Scholar]
  28. Tang ZY, Yu YQ, Zhou XD, Ma ZC, Lu JZ, Liu KD, Lin ZY, Yang BH, Fan Z, Hou Z, Zhang M (1991a) Cytoreduction and sequential resection: a hope for unresectable primary liver cancer. J Surg Oncol 47:27–31 [DOI] [PubMed] [Google Scholar]
  29. Tang ZY, Zhou HY, Zhao G, Chai LM, Zhou M, Lu JZ, Liu KD, Havas HF, Nauts HC (1991b) Preliminary result of mixed bacterial vaccine as adjuvant treatment of hepatocellular carcinoma. Med Oncol Tumor Pharmacother 8:23–28 [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES